<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2926">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01334749</url>
  </required_header>
  <id_info>
    <org_study_id>ISD-DEDEMAS-01</org_study_id>
    <nct_id>NCT01334749</nct_id>
  </id_info>
  <brief_title>Observational Study on Determinants of Dementia After Stroke</brief_title>
  <acronym>DEDEMAS</acronym>
  <official_title>Determinants of Dementia After Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the DEDEMAS (Determinants of Dementia After Stroke) study is to identify&#xD;
      predictors of post stroke dementia (PSD). A particular focus will be on biological markers&#xD;
      (neuroimaging, biochemical markers derived from blood) and on interactions between vascular&#xD;
      and neurodegenerative mechanisms. For this purpose patients with an acute stroke and without&#xD;
      prior dementia will be followed for 10 years.&#xD;
&#xD;
      Note: Starting from 01.01.2014 this study is expanded to a multi-centric design funded by the&#xD;
      German Center for Neurodegenerative Diseases (The DZNE - Mechanisms of Dementia After Stroke&#xD;
      (DEMDAS) Study). This includes the following study sites: DZNE/München - Institute for Stroke&#xD;
      and Dementia Research, Klinikum der Universität München (Coordinator); DZNE/Berlin -&#xD;
      Neuroscience Research Center - Campus Mitte Charité; DZNE/Bonn - Klinik und Poliklinik für&#xD;
      Neurologie, Universitätsklinikum Bonn; DZNE/Göttingen - University Medical Center Göttingen;&#xD;
      DZNE/Magdeburg - Universitätsklinikum Magdeburg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Risk of dementia is high after stroke but the mechanisms of post stroke dementia (PSD) are&#xD;
      insufficiently understood. Specifically, there are few data on how vascular and&#xD;
      neurodegenerative mechanisms interact in determining cognitive decline after stroke. The&#xD;
      primary aim of the DEDEMAS/DEMDAS (Determinants of Dementia After Stroke) study is to&#xD;
      identify predictors of PSD. A particular focus will be on biological markers (neuroimaging,&#xD;
      biochemical markers derived from blood) and on interactions between vascular and&#xD;
      neurodegenerative mechanisms. Patients with an acute stroke and without prior dementia will&#xD;
      be followed for 5 years with assessments at baseline (&lt; 72 h after onset of stroke), and at&#xD;
      3, 6, 12, 24, 36, 48, and 60 months. In addition, DEDEMAS patients will have an annual&#xD;
      telephone follow-up from year 6 to 10. Baseline assessments will include variables previously&#xD;
      demonstrated to be associated with PSD as well as novel variables. Brain MRI (structural MRI&#xD;
      and resting state fMRI) in combination with detailed neuropsychological testing and blood&#xD;
      draws will be done at 6, 12, 36, and 60 months. Patients developing cognitive impairment&#xD;
      (with or without dementia) and a subgroup of matched individuals without cognitive decline&#xD;
      will be examined by brain FDG-PET and Amyloid-PET scanning. Lumbar puncture will be done on&#xD;
      patients who develop cognitive impairment and thus have a clinical indication for the&#xD;
      procedure. Efforts will be made to classify demented patients into diagnostic categories&#xD;
      (Vascular Dementia, Mixed Dementia, Alzheimer's disease, other categories). Predictive&#xD;
      factors for PSD will be identified using multiple Cox-proportional hazards models. Apart from&#xD;
      providing insights into the mechanisms of PSD this study holds the potential to identify&#xD;
      novel diagnostic markers and novel targets for preventive therapies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2011</start_date>
  <completion_date type="Anticipated">January 2029</completion_date>
  <primary_completion_date type="Anticipated">January 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>dementia occurrence</measure>
    <time_frame>5 years in DEMDAS</time_frame>
    <description>this evaluation will be based on a neurological and general clinical examination, and on the evaluation of activities of daily life using the instrumental activities daily life scale after an interview with the patient and his/her family</description>
  </primary_outcome>
  <primary_outcome>
    <measure>dementia occurrence</measure>
    <time_frame>10 years in DEDEMAS</time_frame>
    <description>this evaluation will be based on a neurological and general clinical examination, and on the evaluation of activities of daily life using the instrumental activities daily life scale after an interview with the patient and his/her family</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>dementia occurrence</measure>
    <time_frame>6 months</time_frame>
    <description>this evaluation will be based on a neurological and general clinical examination, and on the evaluation of activities of daily life using the instrumental activities daily life scale after an interview with the patient and his/her family</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dementia occurrence</measure>
    <time_frame>12 months</time_frame>
    <description>this evaluation will be based on a neurological and general clinical examination, and on the evaluation of activities of daily life using the instrumental activities daily life scale after an interview with the patient and his/her family</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dementia occurrence</measure>
    <time_frame>36 months</time_frame>
    <description>this evaluation will be based on a neurological and general clinical examination, and on the evaluation of activities of daily life using the instrumental activities daily life scale after an interview with the patient and his/her family</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive impairment</measure>
    <time_frame>6 months</time_frame>
    <description>Impairment of some tests of cognitive battery without significant impairment in activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive impairment</measure>
    <time_frame>12 months</time_frame>
    <description>Impairment of some tests of cognitive battery without significant impairment in activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive impairment</measure>
    <time_frame>36 months</time_frame>
    <description>Impairment of some tests of cognitive battery without significant impairment in activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive impairment</measure>
    <time_frame>60 months</time_frame>
    <description>Impairment of some tests of cognitive battery without significant impairment in activities of daily living</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">736</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Hemorrhagic Stroke</condition>
  <arm_group>
    <arm_group_label>Acute Stroke</arm_group_label>
    <description>Patients over 18 years and without pre-stroke dementia, displaying an ischemic or hemorrhagic stroke, onset within the last 72 hours, language German</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, plasma, RNA, CSF&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to a specialized stroke service because of an acute stroke.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Language: German&#xD;
&#xD;
          -  Acute stroke that occurred within the last 5 days as defined by:&#xD;
&#xD;
        acute focal neurological deficit in combination with one of the following:&#xD;
&#xD;
          -  An acute ischemic infarct as documented by either a DWI positive lesion on MR imaging&#xD;
             or a new lesion on a delayed CT scan&#xD;
&#xD;
          -  An intracerebral hemorrhage as documented on CT or MRI&#xD;
&#xD;
          -  An informant of the patient is available&#xD;
&#xD;
          -  Written informed consent by patient prior to study participation&#xD;
&#xD;
          -  Willingness to participate in follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  IQCODE &gt; 64 or diagnosis of dementia&#xD;
&#xD;
          -  Patients transferred from an outside stroke unit (to avoid possible selection bias)&#xD;
&#xD;
          -  Patients presenting a stroke going back more than 120 hours&#xD;
&#xD;
          -  Patients presenting one of the following diseases: cerebral venous thrombosis,&#xD;
             traumatic cerebral haemorrhage, intracerebral haemorrhage because of a known or&#xD;
             image-guided assumed vascular malformation, pure meningeal or intraventricular&#xD;
             haemorrhage&#xD;
&#xD;
          -  Patients presenting a malignant disease with life expectancy &lt; 3years&#xD;
&#xD;
          -  Contraindication for MRI&#xD;
&#xD;
          -  Participation in an intervention/AMG-study at baseline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Dichgans, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Stroke and Dementia Research, Klinikum der Universität München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DZNE/Munich-Interdisciplinary Stroke Center Munich, Klinikum der Universität München, Campus Großhadern</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DZNE/Berlin - Neuroscience Research Center - Campus Mitte Charité</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DZNE/Bonn - Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DZNE/Göttingen - University Medical Center Göttingen</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DZNE/Magdeburg - Universitätsklinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.klinikum.uni-muenchen.de/Interdisziplinaeres-Schlaganfallzentrum/en/index.html</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.klinikum.uni-muenchen.de/Institut-fuer-Schlaganfall-und-Demenzforschung/en/index.html</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Wollenweber FA, Zietemann V, Rominger A, Opherk C, Bayer-Karpinska A, Gschwendtner A, Coloma Andrews L, Bürger K, Duering M, Dichgans M. The Determinants of Dementia After Stroke (DEDEMAS) Study: protocol and pilot data. Int J Stroke. 2014 Apr;9(3):387-92. doi: 10.1111/ijs.12092. Epub 2013 Jul 9.</citation>
    <PMID>23834337</PMID>
  </reference>
  <results_reference>
    <citation>Wollenweber FA, Därr S, Müller C, Duering M, Buerger K, Zietemann V, Malik R, Brendel M, Ertl-Wagner B, Bartenstein P, Rominger A, Dichgans M. Prevalence of Amyloid Positron Emission Tomographic Positivity in Poststroke Mild Cognitive Impairment. Stroke. 2016 Oct;47(10):2645-8. doi: 10.1161/STROKEAHA.116.013778. Epub 2016 Aug 18.</citation>
    <PMID>27539301</PMID>
  </results_reference>
  <results_reference>
    <citation>Zietemann V, Kopczak A, Müller C, Wollenweber FA, Dichgans M. Validation of the Telephone Interview of Cognitive Status and Telephone Montreal Cognitive Assessment Against Detailed Cognitive Testing and Clinical Diagnosis of Mild Cognitive Impairment After Stroke. Stroke. 2017 Nov;48(11):2952-2957. doi: 10.1161/STROKEAHA.117.017519. Epub 2017 Oct 17.</citation>
    <PMID>29042492</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 12, 2011</study_first_submitted>
  <study_first_submitted_qc>April 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2011</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Martin Dichgans</investigator_full_name>
    <investigator_title>Prof. Dr. med. M. Dichgans</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Dementia</keyword>
  <keyword>Dementia, Vascular</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Intracranial Hemorrhage</keyword>
  <keyword>Brain Ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Hemorrhagic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

